GlassScriptPhysician profile
Ira Pardo
NPI 1659474443
$5,729.20
in general payments reported to CMS, 2019-2025
24 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $252 · 2021: $582 · 2022: $786 · 2023: $810 · 2024: $889 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,046.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $732.64 | 2019-2025 | Orencia |
| Ucb, INC. | $708.86 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $707.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $379.00 | 2019-2025 | Nucala, Benlysta |
| Lilly USA, LLC | $310.20 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Janssen Biotech, INC. | $289.08 | 2019-2024 | Tremfya |
| Pfizer INC. | $260.70 | 2019-2025 | |
| Amgen INC. | $251.05 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Sobi, INC | $161.77 | 2019-2021 | |
| Horizon Therapeutics Plc | $153.05 | 2019-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $120.15 | 2021 | |
| Mallinckrodt Hospital Products INC. | $114.28 | 2020-2025 | Acthar |
| Alvogen INC | $88.53 | 2023 | Teriparatide |
| Radius Health, INC. | $82.50 | 2019-2025 | Tymlos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Genentech USA, INC. | $58.00 | 2019-2025 | Actemra |
| Alexion Pharmaceuticals, INC. | $52.27 | 2019-2025 | Strensiq |
| Mallinckrodt Enterprises LLC | $44.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.44 | 2023 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.15 | 2021 | |
| Sandoz INC. | $15.26 | 2025 | Jubbonti |
| Aurinia Pharma U.S., INC. | $11.24 | 2021 | |
| Genzyme Corporation | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Pardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.